Multiple Myeloma News
Publisher Correction: Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Belantamab Mafodotin Combination Shows Durable Efficacy in Relapsed or Refractory Multiple Myeloma
Source: Pharmacy Times articles Belantamab mafodotin plus lenalidomide and dexamethasone was found tolerable with no new safety signals and enhanced response rates in patients with multiple myeloma. Read More
Daratumumab Resistance in Multiple Myeloma May Be Associated With High Levels of NHE6 Expression
Source: Pharmacy Times articles Two Houston Methodist cancer researchers were granted a quarter of a million dollars each to study some of the most lethal cancers. Read More
Elevated SFXN2 limits mitochondrial autophagy and increases iron-mediated energy production to promote multiple myeloma cell proliferation
Source: Myeloma : nature.com subject feeds Post Content Read More
I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients
Source: Myeloma : nature.com subject feeds Post Content Read More
Conditioning Regimens Produce Similar Long-Term Outcomes in Newly Diagnosed Multiple Myeloma
Source: Myeloma - Hematology Advisor Conditioning with MEL200 or BUMEL produced similar outcomes at 7 years. Read More
Access to Trials of CAR T-Cell Therapy or Bispecific Antibodies May Vary by Race
Source: Myeloma - Hematology Advisor Black patients with multiple myeloma may not have equitable access to clinical trials of CAR T-cell therapy or bispecific antibodies. Read More
Treatment Advances Have Improved Multiple Myeloma Mortality in the US
Source: Myeloma - Hematology Advisor Researchers sought to determine the mortality trends for patients with multiple myeloma over the past few decades. Read More
Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More